144 related articles for article (PubMed ID: 37900835)
1.
Okubo K; Narita S; Koizumi A; Takahashi Y; Sagehashi R; Mori K; Sobu R; Sato H; Kashima S; Kobayashi M; Yamamoto R; Nara T; Numakura K; Saito M; Nanjo H; Habuchi T
Case Rep Oncol; 2023; 16(1):621-627. PubMed ID: 37900835
[TBL] [Abstract][Full Text] [Related]
2. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract][Full Text] [Related]
3. Treatment-related neuroendocrine prostate cancer with
Ikeda R; Matsuoka Y; Inoue M; Ishikawa A; Akagi K; Kageyama Y
IJU Case Rep; 2024 Mar; 7(2):115-119. PubMed ID: 38440716
[TBL] [Abstract][Full Text] [Related]
4. A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with
Naiki T; Naiki-Ito A; Kawai T; Komatsu H; Nishikawa R; Gonda M; Aoki M; Sugiyama Y; Tasaki Y; Yasui T
IJU Case Rep; 2022 Nov; 5(6):431-435. PubMed ID: 36341200
[TBL] [Abstract][Full Text] [Related]
5. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
[TBL] [Abstract][Full Text] [Related]
6. Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with
Kaitsumaru M; Shiota M; Takamatsu D; Blas L; Matsumoto T; Inokuchi J; Oda Y; Eto M
Int Cancer Conf J; 2023 Apr; 12(2):131-136. PubMed ID: 36896198
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer recurring as small-cell carcinoma with a
Yabusaki R; Yoshimura K; Taku K; Suzuki M
IJU Case Rep; 2022 Nov; 5(6):489-492. PubMed ID: 36341199
[TBL] [Abstract][Full Text] [Related]
8. Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review.
Wu Y; Gao Y; Dou X; Yue J
Onco Targets Ther; 2020; 13():8049-8054. PubMed ID: 32848424
[TBL] [Abstract][Full Text] [Related]
9. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
[TBL] [Abstract][Full Text] [Related]
10. [Neuroendocrine prostate cancer].
Tritschler S; Erdelkamp R; Stief C; Hentrich M
Pathologe; 2018 Jul; 39(4):333-343. PubMed ID: 29946852
[TBL] [Abstract][Full Text] [Related]
11. Treatment-emergent neuroendocrine prostate cancer with a germline
Pandya D; Shah M; Kaplan F; Martino C; Levy G; Kazanjian M; Batter S; Martignetti J; Frank RC
Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33608381
[TBL] [Abstract][Full Text] [Related]
12. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
13. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancer.
Ueki H; Terakawa T; Hara T; Hirata J; Jimbo N; Okamura Y; Bando Y; Furukawa J; Harada K; Nakano Y; Fujisawa M
Jpn J Clin Oncol; 2023 Jun; 53(6):522-529. PubMed ID: 36828781
[TBL] [Abstract][Full Text] [Related]
15. Laparoscopic port-site metastasis as the manifestation of neuroendocrine prostate cancer: Case report and literature review.
Gómez González AM; Mantilla Rey D; Ortiz Zableh AM; de Valencia C; Villareal Trujillo N
Urol Case Rep; 2019 May; 24():100845. PubMed ID: 31211056
[TBL] [Abstract][Full Text] [Related]
16. [A Case of BRCA2 Mutation-Positive Intraductal Carcinoma of the Prostate].
Doi K; Fujii T; Hanamoto M; Takamura K; Nakada T; Sato Y; Ogura K
Hinyokika Kiyo; 2023 Jul; 69(7):189-192. PubMed ID: 37558640
[TBL] [Abstract][Full Text] [Related]
17. Asynchronous tumour quadruplicity: rectosigmoid adenocarcinoma, renal cell carcinoma, prostate adenocarcinoma and neuroendocrine small-cell lung cancer - a case report.
Adwan R; Prošvic P; Prošvicová J; Tomšová M
Rozhl Chir; 2018; 97(9):427-431. PubMed ID: 30470124
[TBL] [Abstract][Full Text] [Related]
18. [Neuroendocrine prostate cancer].
Tritschler S; Erdelkamp R; Stief C; Hentrich M
Urologe A; 2017 Nov; 56(11):1475-1484. PubMed ID: 29063171
[TBL] [Abstract][Full Text] [Related]
19. Differential Activity of PARP Inhibitors in
Taza F; Holler AE; Fu W; Wang H; Adra N; Albany C; Ashkar R; Cheng HH; Sokolova AO; Agarwal N; Kessel A; Bryce A; Nafissi N; Barata P; Sartor AO; Bastos D; Smaletz O; Berchuck JE; Taplin ME; Aggarwal R; Sternberg CN; Vlachostergios PJ; Alva AS; Su C; Marshall CH; Antonarakis ES
JCO Precis Oncol; 2021; 5():. PubMed ID: 34778690
[TBL] [Abstract][Full Text] [Related]
20. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
